Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial
Alexa B Kimball, Martin M Okun, Gerit Mulder
Abstract Not Available
Disclosures: Study supported by AbbVie.
adalimumab; hidradenitis suppurativa; therapeutics
Abstract - 69 Poster PDF - 28
- There are currently no refbacks.